

## Ramucirumab

<b>Cat. No.:</b>	HY-P9920
<b>CAS No.:</b>	947687-13-0
<b>Molecular Formula:</b>	C <sub>285</sub> H <sub>434</sub> N <sub>74</sub> O <sub>88</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	6369.07
<b>Target:</b>	VEGFR
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors <sup>[1]</sup> . Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D <sup>[2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	VEGFR-2

### REFERENCES

[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.

[2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA